Hongda Zhao, Vincy Wing Sze Ho, Kang Liu, Xuan Chen, Hongwei Wu, Peter Ka-Fung Chiu, Lu-Yan Chan, Steffi Kar-Kei Yuen, David Ka-Wai Leung, Alex Qinyang Liu, Chris Ho-Ming Wong, Ivan Ching-Ho Ko, Chi Fai Ng, Dinglan Wu, Jeremy Yuen-Chun Teoh
{"title":"Organoid models in bladder cancer: From bench to bedside?","authors":"Hongda Zhao, Vincy Wing Sze Ho, Kang Liu, Xuan Chen, Hongwei Wu, Peter Ka-Fung Chiu, Lu-Yan Chan, Steffi Kar-Kei Yuen, David Ka-Wai Leung, Alex Qinyang Liu, Chris Ho-Ming Wong, Ivan Ching-Ho Ko, Chi Fai Ng, Dinglan Wu, Jeremy Yuen-Chun Teoh","doi":"10.1177/23523735251330404","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC), one of the most prevalent and aggressive urological malignancies, poses significant challenges in diagnosis, treatment, and recurrence management. Patient-derived organoid provides new directions for the precision diagnosis and treatment of bladder cancer.</p><p><strong>Objective: </strong>To make a comprehensive summary of the current bladder cancer organoid studies.</p><p><strong>Methods: </strong>A comprehensive database search was conducted to provide an in-depth overview of the current state of bladder cancer organoid models, with a focus on their applications in basic research, clinical translation, and therapeutic discovery.</p><p><strong>Results: </strong>We summarized the current bladder cancer organoid studies, highlighting their advantages, such as genetic fidelity and high-throughput drug screening capabilities. Additionally, we also address the challenges, including their limited representation of the tumour microenvironment and technical complexity. Finally, we discuss future directions, including the integration of immunotherapy, the development of co-culture systems, and the exploration of non-invasive sampling methods and organoid-on-chip systems.</p><p><strong>Conclusions: </strong>Traditional pre-clinical models have inherent limitations in mimicking the complexity of human tumours. The emergence of organoid technology has offered a groundbreaking approach to address this challenge, providing an innovative tool for studying tumour biology, genetic alterations, drug screening, and personalized medicine in bladder cancer.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 2","pages":"23523735251330404"},"PeriodicalIF":1.0000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23523735251330404","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bladder cancer (BC), one of the most prevalent and aggressive urological malignancies, poses significant challenges in diagnosis, treatment, and recurrence management. Patient-derived organoid provides new directions for the precision diagnosis and treatment of bladder cancer.
Objective: To make a comprehensive summary of the current bladder cancer organoid studies.
Methods: A comprehensive database search was conducted to provide an in-depth overview of the current state of bladder cancer organoid models, with a focus on their applications in basic research, clinical translation, and therapeutic discovery.
Results: We summarized the current bladder cancer organoid studies, highlighting their advantages, such as genetic fidelity and high-throughput drug screening capabilities. Additionally, we also address the challenges, including their limited representation of the tumour microenvironment and technical complexity. Finally, we discuss future directions, including the integration of immunotherapy, the development of co-culture systems, and the exploration of non-invasive sampling methods and organoid-on-chip systems.
Conclusions: Traditional pre-clinical models have inherent limitations in mimicking the complexity of human tumours. The emergence of organoid technology has offered a groundbreaking approach to address this challenge, providing an innovative tool for studying tumour biology, genetic alterations, drug screening, and personalized medicine in bladder cancer.
期刊介绍:
Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.